Comparing a new drug to Yervoy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, HLX13, against a standard drug called Yervoy for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if HLX13 works as well as Yervoy and has similar safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that has spread or cannot be treated with surgery or local treatments.
- You have at least one tumor that can be measured by imaging scans.
- You have not had any systemic treatment (like pills or IV therapy) for your liver cancer before.
- You are able to do daily activities with minimal help (ECOG score 0 or 1) and have good liver function (Child-Pugh Class A).
- You have not had certain prior treatments like immunotherapy.
- Neither bleeding in the esophagus or stomach from liver disease, nor a tumor clot in the main liver vein.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
This study tests a new medicine (HLX17) against a standard immunotherapy drug (Keytruda) as a first treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if the new medicine works just as well and is safe.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.